Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Provectus Biopharmaceuticals, Inc. (PVCT) had Normalized Income after Taxes of $-5.51M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$0.34M |
|
$-5.43M |
|
-- |
|
$0.34M |
|
$5.63M |
|
$-5.29M |
|
$-0.21M |
|
$-5.51M |
|
$-5.51M |
|
$-5.51M |
|
$-5.51M |
|
$-5.51M |
|
|
Normalized Income after Taxes |
$-5.51M |
$-5.29M |
|
$-5.29M |
|
420.28M |
|
420.28M |
|
$-0.01 |
|
$-0.01 |
|
| Balance Sheet Financials | |
$0.57M |
|
$0.00M |
|
$0.13M |
|
$0.70M |
|
$6.90M |
|
$0.02M |
|
$0.10M |
|
$7.00M |
|
$-6.32M |
|
$-6.30M |
|
$-6.30M |
|
420.28M |
|
| Cash Flow Statement Financials | |
$-3.33M |
|
-- |
|
$3.09M |
|
$0.49M |
|
$0.25M |
|
$-0.24M |
|
$1.24M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.08 |
|
-- |
|
-- |
|
-0.00 |
|
-0.45 |
|
100.00% |
|
-1575.32% |
|
-1575.32% |
|
-1574.76% |
|
-1637.90% |
|
-1615.81% |
|
$-3.33M |
|
-- |
|
-- |
|
-- |
|
0.48 |
|
-- |
|
-- |
|
-- |
|
87.14% |
|
87.35% |
|
-789.26% |
|
87.67% |
|
$-0.01 |
|
$-0.01 |
|
$-0.01 |
|